Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Ibrutinib plus R-CHOP bij jongere patiënt met ‘non-germinal center B-cell’ DLBCL?
jun 2019 | Lymfoom